Innovative Platform Jellagen specializes in marine-sourced Collagen Type Zero derived from jellyfish, offering a unique regenerative medicine solution that can appeal to biotech and medical device companies seeking novel biomaterials.

Strategic Collaborations Recent partnerships with Royal Biologics and Alta Bioscience enhance Jellagen’s research and development capabilities, presenting opportunities to co-develop or supply specialized collagen-based products.

Recognition and Visibility Being a finalist at the OBN Awards in the Medtech category increases Jellagen’s credibility, making it a compelling partner for organizations looking for innovative biotech solutions with proven industry recognition.

Funding and Growth With $10 million in funding and a recent Series A raise, Jellagen is poised for expansion and commercial scaling, creating potential sales opportunities for investors and partners in the biotech supply chain.

Market Focus Positioned within regenerative medicine and scientific research sectors, Jellagen offers opportunities to access research institutions and medtech manufacturers interested in marine-derived collagen innovations.